Literature DB >> 12376582

Plasma adiponectin levels are not associated with fat oxidation in humans.

Norbert Stefan1, Barbora Vozarova, Tohru Funahashi, Yuji Matsuzawa, Eric Ravussin, Christian Weyer, P Antonio Tataranni.   

Abstract

OBJECTIVE: To test the hypothesis that low adiponectin is associated with low fat oxidation in humans. RESEARCH METHODS AND PROCEDURES: We measured plasma adiponectin concentrations in 75 healthy, nondiabetic Pima Indians (age, 28 +/- 7 years; 55 men and 20 women; body fat, 29.7 +/- 7.5%) and 18 whites [(age, 33 +/- 8 years; 14 men and 4 women; body fat, 28.2 +/- 10.8% (means +/- SD)] whose body composition was measured by DXA and 24-hour energy expenditure (24-hour EE) by a respiratory chamber. Respiratory quotient (an estimate of whole-body carbohydrate/lipid oxidation rate) was calculated over 24 hours (24-hour RQ).
RESULTS: Before correlational analyses, waist-to-thigh ratio (WTR) and percentage of body fat (PFAT) were adjusted for age, sex, and race; 24-hour EE was adjusted for fat mass and fat-free mass, and 24-hour RQ were adjusted for energy balance. Plasma adiponectin concentrations were negatively correlated with WTR (r = -0.42, p < 0.0001) and PFAT (r = -0.46, p < 0.0001). There was no correlation between plasma adiponectin concentrations and 24-hour RQ, (r = 0.09, p = 0.36) before or after adjustment for PFAT (r = 0.001, p = 0.99, respectively, partial correlation), and no correlation was found between plasma adiponectin concentrations and 24-hour EE (r = -0.12, p = 0.27). DISCUSSION: Our cross-sectional data do not suggest physiological concentrations of fasting plasma adiponectin play a role in the regulation of whole-body fat oxidation or energy expenditure in resting conditions. Whether administration of adiponectin to individuals with low levels of this hormone will increase their fat oxidation rates/energy expenditure remains to be established.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376582     DOI: 10.1038/oby.2002.138

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  7 in total

1.  Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism.

Authors:  P M Catalano; M Hoegh; J Minium; L Huston-Presley; S Bernard; S Kalhan; S Hauguel-De Mouzon
Journal:  Diabetologia       Date:  2006-05-11       Impact factor: 10.122

2.  Lower total fasting plasma adiponectin concentrations are associated with higher metabolic rates.

Authors:  Nicola Pannacciulli; Joy C Bunt; Emilio Ortega; Tohru Funahashi; Arline D Salbe; Clifton Bogardus; Jonathan Krakoff
Journal:  J Clin Endocrinol Metab       Date:  2006-01-31       Impact factor: 5.958

3.  The arcuate nucleus and neuropeptide Y contribute to the antitumorigenic effect of calorie restriction.

Authors:  Robin K Minor; Miguel López; Caitlin M Younts; Bruce Jones; Kevin J Pearson; Robert Michael Anson; Carlos Diéguez; Rafael de Cabo
Journal:  Aging Cell       Date:  2011-04-05       Impact factor: 9.304

Review 4.  Metabolic Factors Determining the Susceptibility to Weight Gain: Current Evidence.

Authors:  Tim Hollstein; Paolo Piaggi
Journal:  Curr Obes Rep       Date:  2020-06

5.  High molecular mass multimer complexes and vascular expression contribute to high adiponectin in the fetus.

Authors:  H Pinar; S Basu; K Hotmire; L Laffineuse; L Presley; M Carpenter; P M Catalano; S Hauguel-de Mouzon
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

6.  Adipogenic signaling in rat white adipose tissue: modulation by aging and calorie restriction.

Authors:  Min Zhu; Garrick D Lee; Liusong Ding; Jingping Hu; Guang Qiu; Rafa de Cabo; Michel Bernier; Donald K Ingram; Sige Zou
Journal:  Exp Gerontol       Date:  2007-06-06       Impact factor: 4.032

7.  Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects.

Authors:  Haiying Yu; Yan Yang; Muxun Zhang; Huiling Lu; Jianhua Zhang; Hongwei Wang; Katherine Cianflone
Journal:  Nutr Metab (Lond)       Date:  2006-02-10       Impact factor: 4.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.